Page History

The scope of this project is to develop a BIMO Frequently

Asked Questions Forum to be posted on the PHUSE Advance Hub, following the same format as the SEND FAQ

Forum. This forum will

use questions brought forward by the pharma/CRO community via public review, presentations, PHUSE BIMO team members,

and so on.

The FDA drafted the initial Bioresearch Monitoring Technical Conformance Guide in December 2017, with an updated version published in July 2020. Reference: Bioresearch Monitoring Technical Conformance Guide - Guide https://www.fda.gov/media/85061/download The . The guide provides specifications for preparing and submitting the following components in electronic format that are used by the FDA for the planning of Bioresearch Monitoring bioresearch monitoring (BIMO) inspections.:

• Clinical Study-Level Information
• Subject-Level Data Line Listings by Clinical Site
• Summary-Level Clinical Site Dataset (clinsite.xpt)

The NDA, BLA , and supplemental submissions to the FDA require BIMO as a critical part of the electronic application. Pharma companies and CROs have individually developed BIMO standards based on the recent guidance from the FDA. A coordinated approach to responses to Frequently frequently asked BIMO questions can benefit sponsors as well as the FDA.

It was apparent during the creation of the PHUSE Bioresearch Monitoring Data

Reviewer’s Guide (BDRG) that organisations implementing BIMO

submission packages have outstanding questions. The BDRG team captured a lot of those questions in our Communication Tracker (repository of questions and team responses). While most questions were directed at the BDRG effort, there were many general questions that came up during review, presentations

etc.